AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15944791 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-based combination chemotherapy (CTX)
Number of subjects: 63
Study 15944791 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy (no-CTX)
Number of subjects: 63
Study 15944791 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line chemotherapy (CTX)
Number of subjects: 63
Study 15944791 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line chemotherapy (CTX)
Number of subjects: 63
Study 12582393 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical methyl aminolevulinate (MAL) 160 mg/g
Number of subjects: 80
Study 12582393 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 80
Study 10226473 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% oxygen during exercise
Number of subjects: 10
Study 10226473 — intervention group
Group type: COMPARATOR
Intervention: Room air during exercise
Number of subjects: 10
Study 10684406 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg
Number of subjects: 0
Study 10684406 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin 20 mg
Number of subjects: 0
Study 10684406 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 0
Study 1984374 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo phosphorus nuclear magnetic resonance (31P NMR) spectroscopy
Number of subjects: 42
Study 1984374 — intervention group
Group type: COMPARATOR
Intervention: In vitro halothane/caffeine contracture test
Number of subjects: 42
Study 6404404 — intervention group
Group type: EXPERIMENTAL
Intervention: Home environment
Number of subjects: 9
Study 6404404 — intervention group
Group type: COMPARATOR
Intervention: Hospital environment
Number of subjects: 9
Study 6404404 — intervention group
Group type: EXPERIMENTAL
Intervention: Home environment during activity
Number of subjects: 9
Study 6404404 — intervention group
Group type: COMPARATOR
Intervention: Hospital environment during activity
Number of subjects: 9
Study 6404404 — intervention group
Group type: EXPERIMENTAL
Intervention: Home environment (sphygmomanometry)
Number of subjects: 9
Study 6404404 — intervention group
Group type: COMPARATOR
Intervention: Hospital environment (sphygmomanometry)
Number of subjects: 9
Study 6404404 — intervention group
Group type: EXPERIMENTAL
Intervention: Home environment (diastolic pressure)
Number of subjects: 9
Study 6404404 — intervention group
Group type: COMPARATOR
Intervention: Hospital environment (diastolic pressure)
Number of subjects: 9
Study 30596964 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amoxicillin suspension (50 mg/kg/day) for 3 days
Number of subjects: 15749
Study 30596964 — intervention group
Group type: COMPARATOR
Intervention: Oral co-trimoxazole suspension (8 mg trimethoprim/kg and 40 mg sulfamethoxazole/kg/day) for 5 days
Number of subjects: 15749
Study 29344840 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily
Number of subjects: 120
Study 29344840 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg once daily
Number of subjects: 120
Study 27813031 — intervention group
Group type: EXPERIMENTAL
Intervention: IV dexketoprofen trometamol (50 mg)
Number of subjects: 60
Study 27813031 — intervention group
Group type: EXPERIMENTAL
Intervention: IV acetaminophen (1 gr)
Number of subjects: 60
Study 27813031 — intervention group
Group type: COMPARATOR
Intervention: No analgesic (Control Group K)
Number of subjects: 60
Study 24008791 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsular tension ring (CTR)
Number of subjects: 34
Study 24008791 — intervention group
Group type: COMPARATOR
Intervention: Control (only IOL)
Number of subjects: 34
Study 22617396 — intervention group
Group type: EXPERIMENTAL
Intervention: BOLUS (25 g of whey protein + 5 g of leucine dissolved in artificially sweetened water; 1 × 500 mL)
Number of subjects: 12
Study 22617396 — intervention group
Group type: EXPERIMENTAL
Intervention: PULSE (15 × 33‐mL aliquots of BOLUS drink every 15 min)
Number of subjects: 12
Study 22617396 — intervention group
Group type: COMPARATOR
Intervention: PLAC (artificially sweetened water)
Number of subjects: 12
Study 20033128 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 0
Study 20033128 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral microwave therapy (TUMT)
Number of subjects: 0
Study 20033128 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted techniques
Number of subjects: 0
Study 20033128 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar resection
Number of subjects: 0
Study 17276321 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing training for dietitians
Number of subjects: 209
Study 17276321 — intervention group
Group type: COMPARATOR
Intervention: Control dietitians (no training)
Number of subjects: 209
Study 15690909 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepon 0.04% ointment
Number of subjects: 126
Study 15690909 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunomax 200 units intramuscularly, administered 3 times every 2nd day
Number of subjects: 126
Study 15690909 — intervention group
Group type: COMPARATOR
Intervention: Routine surgical treatment and drug therapy (control group)
Number of subjects: 126
Study 12577246 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amifostine (200 mg/m2/d in a short 3‐minute infusion 15 to 30 minutes before each fraction of radiotherapy)
Number of subjects: 54
Study 12577246 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous amifostine (500 mg/d in two, slow 1.25‐mL injections at two different sites 20 to 60 minutes before each radiotherapy fraction)
Number of subjects: 54
Study 9660331 — intervention group
Group type: EXPERIMENTAL
Intervention: Polylactic acid bioabsorbable barrier
Number of subjects: 10
Study 9660331 — intervention group
Group type: COMPARATOR
Intervention: ePTFE non-resorbable barrier
Number of subjects: 10
Study 7806089 — intervention group
Group type: COMPARATOR
Intervention: Erythropoietin (Epo) evaluation in endurance runners
Number of subjects: 46
Study 7806089 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) evaluation during a 6-hour race
Number of subjects: 46
Study 2590272 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-layered polyurethane foam wound dressing (Lyomousse)
Number of subjects: 41
Study 2590272 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment specified)
Number of subjects: 41
Study 30732181 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation using red and infrared LEDs (660 nm and 850 nm) with a power of 3.5 mW per LED, 6 sessions over 2 weeks.
Number of subjects: 33
Study 30732181 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (details not specified).
Number of subjects: 33
Study 30732181 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified).
Number of subjects: 33
Study 28743343 — intervention group
Group type: EXPERIMENTAL
Intervention: HD + HF + HP group (HD for 8 times a month + HF for 4 times a month + HP once a month)
Number of subjects: 120
Study 28743343 — intervention group
Group type: EXPERIMENTAL
Intervention: HD + HF group (HD for 8 times a month + HF once a month)
Number of subjects: 120
Study 28743343 — intervention group
Group type: COMPARATOR
Intervention: HD group (HD for 8 times a month)
Number of subjects: 120
Study 25567758 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led behavioral management intervention (tailored DM and HTN content)
Number of subjects: 377
Study 25567758 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-tailored, non-interactive information)
Number of subjects: 377
Study 23505124 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 9.75 mg IM injection
Number of subjects: 201
Study 21682350 — intervention group
Group type: EXPERIMENTAL
Intervention: DRV/r monotherapy (800/100 mg once daily)
Number of subjects: 256
Study 21682350 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (two NRTIs + DRV/r)
Number of subjects: 256
Study 21682350 — intervention group
Group type: EXPERIMENTAL
Intervention: DRV/r monotherapy
Number of subjects: 256
Study 21682350 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 256
Study 19623782 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer factor
Number of subjects: 22
Study 19623782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 15900378 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 40 mg/kg/day in 5% dextrose
Number of subjects: 26
Study 15900378 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose (placebo)
Number of subjects: 26
Study 10480768 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic hyperglycemia
Number of subjects: 8006
Study 10480768 — intervention group
Group type: EXPERIMENTAL
Intervention: Known diabetes
Number of subjects: 8006
Study 10480768 — intervention group
Group type: EXPERIMENTAL
Intervention: High-normal glucose tolerance
Number of subjects: 8006
Study 10480768 — intervention group
Group type: COMPARATOR
Intervention: Low-normal glucose tolerance
Number of subjects: 8006
Study 8688215 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with cisplatin (100 mg/m2, D1) and fluorouracil (1 g/m2, D2‐4) followed by regional treatment
Number of subjects: 121
Study 8688215 — intervention group
Group type: COMPARATOR
Intervention: Regional treatment alone
Number of subjects: 121
Study 2019663 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine
Number of subjects: 114
Study 2019663 — intervention group
Group type: COMPARATOR
Intervention: Quinidine
Number of subjects: 114
Study 7094361 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone infusion
Number of subjects: 6
Study 7094361 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (Control)
Number of subjects: 6
Study 31095004 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy initiation
Number of subjects: 181
Study 29076171 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (2 sessions weekly for 12 weeks)
Number of subjects: 59
Study 29076171 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-FODMAP diet (3 sessions of nutritional counselling over 12 weeks)
Number of subjects: 59
Study 26979982 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted motivational social network intervention (four biweekly sessions using motivational interviewing)
Number of subjects: 60
Study 26979982 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 60
Study 25017530 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray (FFNS) 110 mcg once daily
Number of subjects: 373
Study 25017530 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 373
Study 22189199 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day
Number of subjects: 5411
Study 22189199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5411
Study 19958238 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 36
Study 19958238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 17400672 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial septostomy
Number of subjects: 11
Study 17400672 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 11
Study 17400672 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental O2 therapy
Number of subjects: 11
Study 15724143 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose levothyroxine (L-T(4)), mean dose 320 microg/day, adjunctive treatment for 7 weeks
Number of subjects: 10
Study 15724143 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched healthy women without L-T(4) treatment)
Number of subjects: 10
Study 12040338 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-hour patency group
Number of subjects: 80
Study 12040338 — intervention group
Group type: COMPARATOR
Intervention: 6-hour occlusion group
Number of subjects: 80
Study 12040338 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP level at 24 hours
Number of subjects: 80
Study 9471040 — intervention group
Group type: EXPERIMENTAL
Intervention: Casodex 50 mg daily
Number of subjects: 390
Study 9471040 — intervention group
Group type: EXPERIMENTAL
Intervention: Casodex 100 mg daily
Number of subjects: 390
Study 9471040 — intervention group
Group type: EXPERIMENTAL
Intervention: Casodex 200 mg daily
Number of subjects: 390
Study 9471040 — intervention group
Group type: EXPERIMENTAL
Intervention: Casodex (all doses)
Number of subjects: 390
Study 7613148 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral provocation tests (OPTs) with the suspected drug
Number of subjects: 128
Study 7613148 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant ARs to other mild analgesics during OPTs
Number of subjects: 128
Study 7613148 — intervention group
Group type: COMPARATOR
Intervention: Oral provocation tests (OPTs)
Number of subjects: 128
Study 7613148 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard battery of different analgesics in OPTs
Number of subjects: 128
Study 7613148 — intervention group
Group type: COMPARATOR
Intervention: Single preparation recommendation (e.g., acetaminophen) without OPT
Number of subjects: 128
Study 2375235 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol and norethisterone acetate
Number of subjects: 119
Study 2375235 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate
Number of subjects: 119
Study 2375235 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon calcitonin
Number of subjects: 119
Study 2375235 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 119
Study 31974691 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate total-body CT (iTBCT) scanning
Number of subjects: 1083
Study 31974691 — intervention group
Group type: COMPARATOR
Intervention: Conventional imaging and selective CT
Number of subjects: 1083
Study 31298405 — intervention group
Group type: EXPERIMENTAL
Intervention: 40:1 MI/DCI ratio, 2 g of inositols twice a day for 3 months
Number of subjects: 56
Study 31298405 — intervention group
Group type: EXPERIMENTAL
Intervention: Other ratios (1:3.5, 2.5:1, 5:1, 20:1, 80:1 MI/DCI)
Number of subjects: 56
Study 31298405 — intervention group
Group type: EXPERIMENTAL
Intervention: DCI alone
Number of subjects: 56
Study 28091438 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 ml/kg of 0.25% bupivacaine
Number of subjects: 56
Study 28091438 — intervention group
Group type: COMPARATOR
Intervention: 0.5 ml/kg of 0.25% bupivacaine
Number of subjects: 56
Study 27443567 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer (SV)
Number of subjects: 466
Study 27443567 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet (CC) with Sevelamer (SV)
Number of subjects: 466
Study 27443567 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet (CC) with Calcium Salts (CS)
Number of subjects: 466
Study 27443567 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D (VD)
Number of subjects: 466
Study 24981180 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia (SA)
Number of subjects: 80
Study 24981180 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 80
Study 24981180 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia (SA) and General Anesthesia (GA)
Number of subjects: 80
Study 23075681 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus pemetrexed (PC group)
Number of subjects: 288
Study 23075681 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus cisplatin (GC group)
Number of subjects: 288
Study 20578934 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 309
Study 20578934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study 17624996 — intervention group
Group type: COMPARATOR
Intervention: Single-blind placebo administration
Number of subjects: 321
Study 16371156 — intervention group
Group type: EXPERIMENTAL
Intervention: Human metapneumovirus (hMPV) detection in AE-COPD patients
Number of subjects: 130
Study 16371156 — intervention group
Group type: COMPARATOR
Intervention: Control group (stable COPD)
Number of subjects: 130
Study 16371156 — intervention group
Group type: COMPARATOR
Intervention: Control group (smokers without COPD)
Number of subjects: 130
Study 12048340 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephonic nursing case management
Number of subjects: 111
Study 12048340 — intervention group
Group type: COMPARATOR
Intervention: Standard nursing care
Number of subjects: 111
Study 10624256 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk assessment and classification of pressure ulcers performed daily by nurses using the Modified Norton Scale (MNS) and a 'Pressure Ulcer Card'.
Number of subjects: 0
Study 10624256 — intervention group
Group type: COMPARATOR
Intervention: Control group where risk assessment and classification of pressure ulcers was not performed.
Number of subjects: 0
Study 10624256 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical use of the Modified Norton Scale (MNS).
Number of subjects: 0
Study 10624256 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who were confused on arrival.
Number of subjects: 0
Study 10624256 — intervention group
Group type: COMPARATOR
Intervention: Comparison of reported prevalence of pressure ulcers between experimental and control groups.
Number of subjects: 0
Study 7611822 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical IFN gamma-1 beta gel
Number of subjects: 33
Study 7611822 — intervention group
Group type: COMPARATOR
Intervention: Laser surgery
Number of subjects: 33
Study 2095801 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol gum chewed for 15 minutes after meal ingestion
Number of subjects: 5
Study 2095801 — intervention group
Group type: COMPARATOR
Intervention: Fast-food meals without chewing gum
Number of subjects: 5
Study 329980 — intervention group
Group type: EXPERIMENTAL
Intervention: adriamycin-cis-dichlorodiammineplatinum(II) (cis-platinum)
Number of subjects: 23
Study 329980 — intervention group
Group type: COMPARATOR
Intervention: adriamycin-cyclophosphamide
Number of subjects: 23
Study 31441893 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNTA injection (5 IU/cm)
Number of subjects: 45
Study 31441893 — intervention group
Group type: COMPARATOR
Intervention: Saline injection (control)
Number of subjects: 45
Study 27683185 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (2000 mg) and Vitamin D (1000 IU) supplementation
Number of subjects: 748
Study 26123629 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (100-600 mg/day)
Number of subjects: 63
Study 26123629 — intervention group
Group type: COMPARATOR
Intervention: Clonazepam (0.5-2 mg/day)
Number of subjects: 63
Study 26123629 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of Gabapentin and Clonazepam
Number of subjects: 63
Study 23175556 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral artesunate 6 mg/kg/d (once-daily or twice-daily) for 7 days
Number of subjects: 159
Study 23175556 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral artesunate 8 mg/kg/d (once-daily or twice-daily) for 3 days, followed by mefloquine
Number of subjects: 159
Study 23175556 — intervention group
Group type: COMPARATOR
Intervention: All treatment arms (including both doses and schedules)
Number of subjects: 159
Study 21397453 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-bearing (MB) total knee arthroplasty
Number of subjects: 89
Study 21397453 — intervention group
Group type: COMPARATOR
Intervention: Fixed-bearing total knee arthroplasty
Number of subjects: 89
Study 19848563 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic decision-support tools embedded in the EMR
Number of subjects: 64150
Study 19848563 — intervention group
Group type: COMPARATOR
Intervention: Control group (no electronic decision-support tools)
Number of subjects: 64150
Study 17352022 — intervention group
Group type: EXPERIMENTAL
Intervention: VSL#3 (one sachet t.i.d.)
Number of subjects: 490
Study 17352022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 490
Study 15532847 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus preoperative treatment with recombinant human IL‐2 (9,000,000 IU for three consecutive days)
Number of subjects: 39
Study 15532847 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (control group)
Number of subjects: 39
Study 15532847 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus preoperative treatment with recombinant human IL‐2
Number of subjects: 39
Study 11804379 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy for small-cell lung cancer (SCLC)
Number of subjects: 0
Study 11804379 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery or palliative chemotherapy for non-small-cell lung cancer (NSCLC)
Number of subjects: 0
Study 11804379 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life measurement tools (EORTC LC-13, FACT-L, LCSS)
Number of subjects: 0
Study 11804379 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-validated tools and poor methods of data analysis
Number of subjects: 0
Study 9134073 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide mesylate
Number of subjects: 235
Study 9134073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study 7894627 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% levocabastine eye drops and nasal spray plus topical placebos (twice daily)
Number of subjects: 110
Study 7894627 — intervention group
Group type: COMPARATOR
Intervention: 2% sodium cromoglycate eye drops and nasal spray (four times daily)
Number of subjects: 110
Study 3499074 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate suspension (1 g/10 ml every four hours)
Number of subjects: 74
Study 3499074 — intervention group
Group type: COMPARATOR
Intervention: Antacid titration (to maintain a gastric pH of more than 4)
Number of subjects: 74
Study 31148204 — intervention group
Group type: EXPERIMENTAL
Intervention: TEG-guided transfusion strategy
Number of subjects: 96
Study 31148204 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC)
Number of subjects: 96
Study 29609205 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioner screening for anxiety and depression
Number of subjects: 0
Study 29609205 — intervention group
Group type: COMPARATOR
Intervention: Usual care (screening for pain intensity)
Number of subjects: 0